Company intelligence / Profile preview

Prime Progression

Cambridge, Massachusetts, United Statesprimeprogression.in ↗

Ownership: Private
Employees: ~110
Development stage: Other

Overview

Prime Medicine is advancing a pipeline of genetic therapies using its proprietary Prime Editing platform. The company has demonstrated preclinical proof-of-concept in multiple programs and is entering early clinical trials. Initial data from the Phase 1/2 trial of PM359 for CGD is expected in 2025. Preclinical programs targeting Wilson’s Disease and AATD have shown promising editing efficiency and restoration of normal protein function. The company recently restructured to focus on high-value programs after deprioritizing some earlier efforts.

Therapeutic areas: Rare DiseasesImmunology
Modalities: Gene therapymRNA-based drugsLipid nanoparticle delivery therapyCRISPR-based therapy
Industry: Biotech

Partnerships

Bristol Myers Squibb – collaboration on ex vivo T-cell therapiesBroad Institute – scientific founders’ affiliation

Beyond the preview

Go deeper on Prime Progression.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prime Progression.

Explore the full profile